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ABSTRACT 
Survival rates for patients with Wilms’ tumour (WT) approximate 90% with refined use of 
currently available interventions. However, a subgroup of patients with initial high-risk 
histopathology or relapsing disease have a poor prognosis and it is a challenge to identify and 
prioritise the development of new innovative approaches for these subgroups. We conducted 
a systematic literature search for published phase I and II clinical trials that registered patients 
with WTs, and characterised the early-phase trial activity, quantified response rates and 
highlighted avenues for further development. We identified 63 trials (48 phase I, three phase 
I/II, and 12 phase II trials) enrolling 214 patients with WTs, alongside other malignancies. The 
number of annually recruited WTs did not change significantly and was less than 20% of the 
potential candidates. The vast majority of the trials were conducted in North America and 56 
different interventions were investigated, including conventional chemotherapy and 
biologically-targeted therapies. Overall, 33 WTs revealed some degree of tumour control. Of 
these, five patients demonstrated complete remission (2%), 15 patients partial response (7%) 
and 13 patients stable disease (6%). None of the included novel biologically-targeted 
therapies emerged as promising interventions and only conventional chemotherapy was able 
to induce a complete and partial response. We conclude that early phase trial recruitment of 
WTs is below expected and the clinical outcome of the included patients is dismal. 
Improvement of the availability and recruitment to early-phase trials for WT, especially in 
Europe, is needed.  
 
Keywords Wilms’ tumour, phase I/II trials, relapse, refractory, targeted therapy, 
chemotherapy. 
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1. Introduction 
Wilms’ tumour (WT) is the most common paediatric renal tumour, affecting approximately 1 
in 10,000 children, with a peak incidence at three years of age [1]. Nearly 1,000 new cases are 
diagnosed in Europe every year, and 600 in the United States. Disease-free survival rates 
approximating 90% can be achieved with optimised use of currently-available interventions 
[2-4]. However, a subset of patients still have a poor prognosis, which is linked to high-risk 
histopathology, especially with advanced-stage disease and/or when disease relapse occur. 
In addition, one in four survivors experience severe chronic health conditions related to the 
antitumour therapies that they have received [5]. 
One standard treatment for localised low- and intermediate-risk histology WT is a two drug 
regimen, vincristine and actinomycin D according to the European Société Internationale 
d’Oncologie Pédiatrique (SIOP) protocol [6]. A third drug, doxorubicin is further added in 
metastatic cases. Radiotherapy is administered for most patients with residual tumour after 
nephrectomy and for persistent (drug resistant) metastases predominantly occurring in the 
lungs [7,8]. Interestingly, it is known that WT was the first metastatic solid tumour to 
demonstrate response to chemotherapy in the mid 1950’s and that radiotherapy and 
actinomycin D were remarkably synergistic [9]. Accordingly, at least two thirds of children 
with WT are currently treated successfully with refinement of drug regimens and 
radiotherapy that were introduced in clinical practice more than 50 years ago.  
  
For approximately 10% of patients diagnosed with high-risk histology WT (blastemal type 
remaining after pre-operative chemotherapy or diffuse anaplasia), standard treatment 
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additionally includes carboplatin, etoposide, and cyclophosphamide [7,8]. Despite 
intensification of therapy, such patients, maintain unsatisfactory overall survival rates with 
one third succumbing to their disease if presenting with metastases (table 1).   
 
‘Second-line’ chemotherapy for relapsed or refractory WT depends on which drugs have been 
previously used upfront but is usually based on ifosfamide or cyclophosphamide, carboplatin 
and etoposide combined with irradiation and attempt of surgical resection [10]. The 
introduction of these drugs subsequently to phase II trials [11-14] led to improved post-
recurrence disease-free survival rates ranging between 30% and 70% depending on the initial 
treatment and primary tumour histology [15,16]. Unlike ‘first-line’ treatment, ‘second-line’ 
chemotherapy is not based on evidence from randomised trials, but solely on prospective 
single arm studies and case series. Alternative chemotherapy (e.g., irinotecan, topotecan and 
temozolamide) or a further increase in dose intensity, like those reached in myeloid-ablative 
regimens, have demonstrated limited evidence for improvement in survival rates [17-20].  
 
Of all the 1,600 WTs expected to occur annually across countries who apply the clinical 
protocols of the SIOP-RTSG and COG, approximately 15% will recur or have refractory disease 
to initial chemotherapy regimens, of whom about 50% eventually fail to second line 
conventional chemotherapy. Hence, we would expect that more than 100 relapsed patients 
yearly are ultimately potential candidates for entering early-phase clinical trials on new or 
alternative drugs. Therefore, the aim of this review is to establish the level of phase I and II 
trial activity and outcomes reported for patients with WT over the last 10 years and discuss 
potential areas for improvement and related actions for optimising development of new 
therapeutic strategies. 
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2. Methods 
2.1. Inclusion criteria 
We searched for any phase I or II early phase clinical trial published in 2005 onwards that 
have enrolled relapsed or refractory WT to any previous treatment regimen. We excluded 
studies not registered as phase I/II studies. Likewise, we did not include phase I/II trials 
focusing on supportive care. 
 
2.2. Search strategy 
We identified phase I and II trials in Medline (Pubmed) and hand-searched relevant 
conference abstract books (SIOP, ASCO (American Society of Clinical Oncology) and ASPHO 
(American Society of Pediatric Hematology/Oncology) meetings) for additional trials. We 
searched for registered clinical trials and registered trials 
on http://clinicaltrials.gov, http://who.int/trialsearch/ and the European ITCC (Innovative 
Therapies for Children with Cancer) and North American  Children’s Oncology Group (COG) 
homepages. The last search was carried out in July 2016. We used the key search terms: 
‘Wilms’ or ‘nephroblastoma’, ‘solid tumour’, ‘paediatric’ or children’ and phase I/II trial. 
There were no language restrictions. Two authors (JB and FS) screened the titles and 
abstracts for relevant trials identified by the search strategy. Disagreements were resolved 
by discussion. Authors of the included trials were contacted by e-mail if additional 
information was needed.  
 
2.3. Data extraction 
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We identified the first author’s name, responsible group/country, reported funding/support 
(non-profit, for-profit, or both), publication year and journal or conference, phase of trial (I 
or II) and design, inclusion criteria, number of patients with WT and with other solid tumour 
enrolled, drug/treatment regimen tested, and evaluation of target lesions (complete 
remission (CR), partial response (PR), stable disease (SD), and progressive disease (PD) for 
patients with WT. 
 
2.4. Response criteria 
We defined a ‘response’ to treatment depending on whether the patients obtained CR 
(disappearance of lesion(s)), PR (at least 30% decrease in the sum of diameters of target 
lesions) or SD (insufficient shrinkage to qualify for PR nor sufficient increase to qualify for 
PD) [21]. Tumour response was assessed and reported according to the RECIST criteria by 
the individual trials. Whether SD is a specific response related to treatment is debatable. 
However, as WT is a rapidly growing tumour and many patients entered the early phase 
trials with progressive disease, we considered SD a clinical response for purpose of this 
study.  
 
3. Results 
We identified 63 trials enrolling at least one patient with a WT (Table 2) (references in 
Appendix A). Of these, 48 were phase I trials, three embedded phase I/II, and 12 phase II on 
relapse or refractory paediatric solid tumours. All studies were non-randomised and 56 
different interventions were investigated. Two studies included solely patients diagnosed 
with WT [22,23]. The remaining studies enrolled WT cases alongside various paediatric solid 
and/or haematological cancers. Overall, the identified trials enrolled 214 patients with WT 
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(range 1-25). We previously estimated that each year at least 100 relapsed patients in North 
America/Europe were potential candidates for early-phase clinical trials. Hence, 19% (214 out 
of 1,100 WTs from 2005-2016) of the candidates were enrolled in published trials in the study 
period. Through the years of reporting the number of published trials and number of recruited 
WTs per year did not indicate a significant trend towards increased or reduced activity (fig 1 
and 2).  
 
Fifty-four studies (86%) were conducted in North America, predominantly as multi-
institutional cooperative trials through the COG and National Cancer Institute (NCI) 
collaboration. One trial was conducted in South America, one in Japan, and six trials (10%) 
were conducted in Europe, with two by the ITCC. A single trans-Atlantic trial has recently been 
published (table 2). Forty-one trials (65%) were supported by both for-profit and non-profit 
organisation, 15 trials were supported only by non-profit, three trials by for-profit and four 
trials had unclear funding status. 
 
In 17 trials, solely licensed cytotoxic chemotherapeutic agent(s) rarely incorporated in front-
line standard protocols was administered. Novel agents or alternative non-chemotherapeutic 
compounds were assessed in 54 trials, either as monotherapy (83%) or combined with 
chemotherapy (17%). The most frequently used cytotoxic agents were irinotecan (ten trials), 
oxaliplatin (five trials) and cyclophosphamide (five trials). The novel agent trials encompassed 
a heterogeneous group of immunotherapy, receptor inhibitors, and differentiating agents. 
These agents mainly belonged to the biologically-targeted therapies of tyrosine kinase 
inhibitors or VEGF/IGF antibodies, most frequently sorafenib (four trials), bevacizumab (four 
trials) and cixutumumab (three trials) (table 2). The overall trend was that relatively more 
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novel agents were being investigated over the years of reporting compared to conventional 
chemotherapy (Fig 1).   
 
The majority of trials (92%) reported on the anti-tumour effects for the WTs according to 
the RECIST criteria. For the trials where chemotherapy predominated, a response was 
observed in 25 out of 115 patients; irinotecan (1 PR), topotecan (12 PR), actinomycin 
D/rTNFα (3 CR, 5 SD), vincristine/irinotecan/temozolomide/bevacizumab (2 CR, 1 PR), and 
carboplatin/irinotecan (1 SD) (Table 3). For monotherapy with novel agent a response was 
observed in eight out of 99 patients; gefitinib (2 SD), ixabepilone (1 SD), adenovirus (OCIVIR-
7) (1 PR), Seneca Valley Virus (2 SD), and sorafenib (2 SD) (table 3). Accordingly, overall 33 
WTs revealed some degree of tumour control in early phase trials i.e., five CR, 15 PR, and 13 
SD. Only conventional chemotherapy induced CR and PR (table 3) (appendix B and C). 
Through an ad hoc search at clinicaltrials.gov using the search terms ‘solid tumour’ or 
‘nephroblastoma/Wilms’ and the criteria ‘ongoing study’, ‘0-17 years’ also identified 44 
ongoing early phase I/II studies with the potential to recruit WT patients (July 2016).  
 
4. Discussion 
In this study, we found that approximately 200 patients with relapsed or refractory WT have 
been enrolled in published early phase studies over the last 10 years. As expected, according 
to standard evaluation criteria, only a small proportion of patients demonstrated response to 
treatment. This included a heterogeneous group of traditional chemotherapy to novel 
targeted therapy or a combination of both.  
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Through this review of published early phase trials for WT, we found it clinically important to 
provide the oncologists and researchers with an overview of the activity on new drug 
development, the outcomes on advanced WT, and to identify areas that could potentially be 
improved. We know that our report has limitations. Although we adhered to an exhaustive 
and reproducible search strategy, we may not have identified all relevant studies, for example 
those published in other databases or meeting books that were not included in our search. 
Some potential eligible studies only reported on overall toxicity and did not report about 
inclusion and outcomes of WT. Finally, publication bias will always influence a review as some 
relevant trials remain unpublished. Hence, our review may slightly underestimate the activity 
but we considered it less likely that a significant number of WT recruited for early phase trials 
have been missed.  
 
Standard treatment recommendations with chemotherapy for relapse/refractory WT have 
been available for many years [10,24]. Accordingly, the patients recruited for the early phase 
trials were mainly either 2nd relapse or advanced refractory disease. Overall, the enrolled WTs 
include a variety of subgroups with prognostically different histological features, like the SIOP 
high-risk (diffuse anaplasia and blastemal-type histology) or intermediate-risk histology WT, 
and the COG unfavourable (histology with anaplasia) or favourable histology. Furthermore, 
acknowledging the additional and substantial intra-tumour genetic heterogeneity highlights 
the complexity of WT treatment and the challenge of gathering a group of WT in trials with 
comparable risk features [5].  
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The considerable improvement in the survival rates for children with WT during the last few 
decades is based on more optimised chemotherapy dosing, timing and intensity rather than 
adoption of novel compounds or strategies. Despite this refinement, children with high-risk 
prognostic features and metastatic disease still have a poor prognosis and the intensified 
treatment for these children comes with significant acute and late toxicities [5,26]. 
Identification of novel therapies is therefore essential [27,28]. Hence, one concern emerging 
from our study is the paucity of patients with recurrent WT tested for new drugs in 
comparison to the number of potential candidates. The number of trials and WT 
recruitment seems consistent throughout our search period, and is in the range of about 20 
patients per year. Hence, the recruitment rate could be strengthened knowing that up to 
100 cases could be eligible each year. This rough estimate illustrates that a considerable 
number of relapsed patients are treated outside controlled clinical trials, and likely with 
regimens with unregistered clinical efficacy. This contrasts the high proportion of children 
with WT enrolled in frontline treatment protocols [6].  
 
There may be multiple explanations for the low accrual rate of children with WT in trials on 
new drugs. The rapid growth of relapsing WT and unavailability of new drug trials locally may 
narrow the window for clinicians and parents to decide on additional trial enrolment and to 
bridge to early phase trials. In addition, marrow and other prolonged toxicities subsequent to 
high-dose chemotherapy (frequently used at first WT relapse) and radiotherapy cause some 
patients to be ineligible for early phase trials due to the strict inclusion criteria. The genetic 
heterogeneity of WT and the low prevalence of known druggable somatic mutations, also 
makes it challenging to design a WT biologically driven new drug trial [26,27]. More 
‘subjective’ reasons may be that WT has a high remission rate achieved frontline and a good 
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response rate in relapsing tumours, which may explain why research on new 
strategies/compounds for WT has attracted less attention and fewer resources than other 
paediatric cancers. In this vein the local responsible clinician may also consider that patients 
with recurrent/refractory WT are still curable, often after multiple lines of chemotherapy 
(outside protocols) and underestimate the poor prognosis for such cases.  
 
Although the acceptable post-relapse outcome for standard-risk patients may justify the use 
of conventional drugs at first relapse, the prognosis is dismal for patients with subsequent 
relapses or with unfavourable features at first relapse [15,29,30]. The latest generation of 
active agents for relapse WT, such as etoposide, carboplatin, ifosfamide, and 
cyclophosphamide have demonstrated objective responses in 50-75% in phase II trials [11-
14]. Intensified use of these drugs is included as backbone treatment for relapsed WT across 
SIOP and COG recommendations. It is noteworthy that convincing evidence for high-dose 
chemotherapy with autologous stem cell rescue remains inadequate despite thorough 
Bayesian analysis of the published evidence [17]. More recently, topoisomerase inhibitors 
(irinotecan and topotecan) have been tested as promising alternatives for subgroups of WT, 
but further evidence is required [18,19,23,31]. 
 
Unfortunately, the recruitment of relapsed WT is scattered throughout many different trials 
resulting in very few patients in each individual trial. Three trials (on topotecan, 
rTNF/actinomycin D and vincristine/irinotecan/temozolomide/bevacizumab, respectively) 
demonstrated some response, but due to such small numbers, it is impossible to make any 
firm recommendations (table 2) [22,23,32]. Looking at the novel agent trials revealed that 
numerous biological interventions were assessed and focus was on anti-angiogenic 
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compounds (inhibitors and antibodies), IGF-1R antibodies and mTOR inhibitors. Compared 
to conventional chemotherapy very few novel agents, such as monotherapy, demonstrated 
tumour response and at best, stable disease. Based on these findings, standard 
chemotherapy currently seems more promising on short-term basis in comparison to the 
use of novel agents for WT. However, the trend is clearly going towards assessing more 
novel agents but we are still awaiting a more promising biologic agent (Table 2). We also 
have to recognise that early phase trials design focuses on toxicity and safety as primary 
endpoints – especially those conducted in the earliest period of this review -, whereas 
tumour response, although reported in the vast majority of the trials, represents a 
secondary outcome endpoint. Therefore some agents may not have shown efficacy because 
they have been tested using suboptimal drug doses or tested in a limited number of 
patients. 
 
Our understanding of WT tumorigenesis is evolving, and several signalling pathways, 
microRNA processing genes and epigenetics are now known to play some roles [33]. A drug 
development approach focusing on renal tumour biology could adequately direct the 
resources for new trials. A recent European drug development workshop focused on a 
comprehensive analysis of WT tumorigenesis and hence proposed a wide range of potential 
biological targets and relative therapies for WT [26,27]. Targeting the aberrant activation of 
the WNT/beta-catenin signalling cascade or the insulin-like growth factor (IGF) signalling 
pathway have been discussed, but not yet transferred into clinical trials. Currently, the most 
WT-focused ongoing early phase trial is targeting the cell-surface glycoprotein CD56 with an 
antibody (lorvotuzumab mertansine) [34]. CD56 is mainly expressed in blastemal 
components. Blastemal predominant histopathologies have a poorer prognosis, therefore 
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lorvotuzumab may be most beneficial for this subgroup [35]. Over the first year this trial has 
impressively recruited 16 patients with WT. 
 
We noticed a contrast between the efforts made on each side of the Atlantic. Only six early-
phase trials have been published in Europe since 2005, as opposed to 54 in North America. 
New drug development programs in North America mainly rely on collaborations between 
the Developmental Therapeutics and the Renal Tumour Committee of the COG and medical 
research agencies (National Institutes of Health and NCI), along with pharmaceutical agency 
input. Adjacently, the Paediatric Preclinical Testing Program in USA systematically tests 
agents’ in vitro and in vivo preclinical models of common childhood cancers. This 
“collaboration” has led to the initiation of several trials including new frontline drug trials 
for high-risk renal tumours. For example, a phase II window trial with irinotecan/vincristine 
in metastatic diffuse anaplastic WT was undertaken as this group of patients traditionally 
had a less than 30% disease-free survival expectancy [29,31]. In Europe, the two analogous 
organisations are the SIOP Renal Tumour Study Group (SIOP-RTSG) and the ITCC consortium, 
and further enhancing a reciprocal collaboration is a priority of The European Network for 
Cancer Research in Children initiative (ENNCA) [36]. Ideally, a trans-Atlantic collaboration 
would ensure adequate early phase trials for the relatively few WT cases, though challenged 
by non-trivial legislative and pharmaceutical logistics. Such collaboration may also facilitate 
a promising novel agents into a joint phase III randomised clinical trial despite the different 
treatment approach/regimen between COG and SIOP. An active interaction and discussion 
between the two disease-specific working groups across the ocean is ongoing.     
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In conclusion, further initiatives are needed to optimise recruitment of relapsed WT patients, 
like the successful COG approach of prioritising a single early phase trial or having a WT-
stratum. The profound clinical and genetic heterogeneity of WT make designing early phase 
trials focusing on WT a challenge. In Europe especially, more available early phase trials are 
required and an organised cooperative effort between the ITCC and the SIOP-RTSG is 
considered a priority to emulate the COG’s fruitful approach to patient recruitment. Efforts 
to channel patients with WT on a biologically rationale basis into a limited number of studies 
presents challenges when needed across several different countries e.g. in Europe. 
Developing such a strategy requires a cooperative approach from the pharmaceutical industry 
and regulatory bodies, with strong parental and patient involvement. 
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Fig. 1. Number of annual phase I and II trials that have reported on Wilms’ tumour patients 
according to year of publication.  
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Fig. 2. Number of patients with Wilms’ tumour included in phase I and II trials according to 
year of publication  
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Table 1 
2-year event free survival and 5-year overall survival for Wilms’ tumour in the SIOP 2001 protocol. 
 
N, number of patients: OS, overall survival; EFS, event free survival  
Source: SIOP WT 2001 database for all patients with stage I-IV Wilms’ tumour treated as per-protocol with pre-op 
chemotherapy, 5,731 patients were registered from 2001-2015. Analysis provided by Harm van Tinteren, trial statistician 
((V Tinteren 2015). 
  
 
Histopathology  
Risk Group 
 
 
Stage I 
 
 
Stage II 
 
 
Stage III 
 
 
Stage IV 
 
 
All 
 
Low Risk (N) 
 
95 
 
6 
 
23 
 
61 
 
185 
2y EFS (%) 97 100 100 91 95 
5y OS (%) 99 100 100 94 98 
 
Intermediate Risk (N) 
 
1352 
 
625 
 
514 
 
389 
 
2880 
2y EFS (%) 92 89 88 81 89 
5y OS (%) 98 97 94 89 96 
 
High Risk (N) 
 
163 
 
115 
 
141 
 
75 
 
494 
2y EFS (%) 91 84 68 31 74 
5y OS (%) 97 82 70 35 76 
 
All (N) 
 
1610 
 
746 
 
678 
 
525 
 
3559 
2y EFS (%) 92 88 84 76 87 
5y OS (%) 98 94 90 82 93 
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Table 2: Published phase I or II trials including at least one patient with Wilms tumour.  
 
Treatment Enrolled solid 
tumours 
Enrolled WT 
(tumour response) 
Phase of trial 
(Origin/Group) 
Funding Author, 
publication year 
Gefitinib 25 2 (2 SD) I (NA/COG) Both Daw, 2005 
Cisplatin/Temozolomide 38 2 (none) I/II (France) NP Geoerger, 2005 
Trabectedin 12 2 (none) I (NA/COG) Both Lau 2005 
Flavopiridol 25 1 (NR)2 I (NA/COG) NP Whitlock, 2005 
ABT-751 (tubulin inhibitor) 24 2 (none) I (NA) Both Fox, 2006 
Depsipeptide 18 2 (none) I (NA) NP Fouladi, 2006 
Irinotecan 16 2 (1 PR) I (Japan) NA Shitara, 2006 
Fenretinide 54 1 (none) I (NA) NP Villablanca, 2006 
Gemcitabine 8 1 (none) II (Germany) Both Wagner-Bohn 2006 
Docetaxel 178 9 (none) II (NA/COG) NP Zwerdling, 2006 
All-trans-retinoic acid/IFN-α2A 32 14 (none)2 II (NA) NP Adamson, 2007 
Irinotecan 161 11 (none) II (NA/COG) NP Bomgaars, 2007 
Pemetrexed 33 1 (none) I (NA/COG) Both Malempati, 2007 
Topotecan 37 25 (12 PR) II (NA) Both Metzger, 2007 
G3139/Doxorubicin/Cyclophosphamide 37 5 (none) I (NA/COG) NP Rheingold 2007 
Oxaliplatin 26 1 (none) I (NA) NP Spunt, 2007 
17-allylaminogeldanamycin  17 2 (none) I (NA/COG) NP Weigel, 2007 
Oxaliplatin 45 2 (none)2 I (France) Both Geoerger, 2008 
Bevacizumab 21 2 (none) I (NA/COG) Both Glade Bender, 2008 
Rebeccamycin analogue 133 7 (none) II (NA/COG) NP Langevin, 2008 
Carboplatin/Irinotecan 28 2 (1 SD) I (NA) NP Levy, 2008 
rTNFα/Actinomycin D 21 19 (3 CR, 5 SD) II (NA) NR Meany, 2008 
Paclitaxel/Ifosfamide 15 1 (none) I (NA/POG) NP Geller, 2009 
Oxaliplatin/irinotecan 16 1 (none) I (NA) NP McGregor, 2009 
Cetuximab/Irinotecan 46 1 (none)2 I (NA/PC) FP Trippett, 2009 
Ixabepilone 19 2 (none) I (NA) NP Widemann, 2009 
Cediranib 16 1 (none) I (NA) Both Fox, 2010 
Ixabepilone 61 10 (1 SD) II (NA/COG) NP Jacobs, 2010 
Adenovirus (OCIVIR-7) 21 1 (1 PR) I (Finland) NP Nokisalmi, 2010 
Ispinesib 24 2 (none) I (NA/COG) NP Souid, 2010 
Vincristine/Irinotecan/Temozolomide  42 2 (none) I (NA/COG) NP Wagner, 2010 
Dasatinib 28 1 (none) I (NA/COG) NP Aplenc, 2011 
Lenalidomide 46 2 (none) I (NA/COG) NP Berg, 2011 
Oxaliplatin/Gemcitabine 93 5 (none) II (EU/ITCC) Both Geoerger 2011 
Temsirolimus 13 1 (none) 2 I (NA) Both Spunt, 2011 
Valproic acid 26 1 (none) I (NA/COG) NP Su 2011 
Plitidepsin 38 4 (none) I (EU/ITCC) FP Geoerger, 2012 
Aflibercept 21 1 (none) I (NA/COG) Both Glader Bender, 2012 
Cyclophosphamide/Topotecan 51 2 (NR) I/II (NA) NP Kasow, 2012 
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Irinotecan 17 3 (none) I (NA) NP McGregor, 2012 
Cixutumumab 47 2 (none) I/II (NA/COG) NP Malempati, 2012 
Lexatumumab 17 1 (none) I (NA) NP Merchant, 2012 
Alisertib 37 2 (none) I (NA/COG) NR Mossé, 2012 
Sorafenib 49 4 (none)2 I (NA/COG) NP Widemann 2012 
Pazopanib 53 1 (none) I (NA/COG) Both Glade-Bender 2013 
Ridaforolimus 18 1 (none) I (NA) NP Gore, 2013 
Oxaliplatin/Doxorubicin 13 1 (none) I (NA) NP Mascarenhas, 2013 
Crizotinib 70 1 (none) I (NA/COG) Both Mosse 2013 
Vorinostat/Bortezomib  23 1 (none) I (NA/COG) NP Muscal, 2013 
Bevacizumab/Sorafenib/Cyclophosphamide 19 1 (none) I (NA) NP Navid 2013 
Imetelstat  20 1 (none) I (NA/COG) NP Thompson 2013 
Vincristine/Irinotecan/Temozolomide/Bevacizumab  13 3 (2 CR, 1 PR) I (NA) NP Venkatramani, 2013 
Bevacizumab/Vincristine/Irinotecan/Temozolamide 13 1 (none) I (NA) NP Wagner 2013 
MK2206 AKT inhibitor  50 1 (none) I (NA/COG) NP Fouladi 2014 
Sorafenib/Irinotecan (abstract) 12 4 (NR) I (NA/COG) NR Meany 2014  
Celecoxib/Thalidomide/Cyclophosphamide/Etoposide  101 3 (NR) II (NA) Both Robison 2014 
Cixutumumab 102 10 (none) II (NA/COG) NP Weigel 2014 
Seneca Valley Virus (NTX-010)  22 3 (2 SD) I (NA/COG) NP Burke, 2015 
Vaccine Racotumomab 14 1 (none) I (Argentina) NP Cacciavillano 2015 
Reovirus (reolysin)/cyclophosphamide 29 3 (NR) I (NA/COG) NP Kolb, 2015 
Cixutumumab/Temsirolimus  39 2 (none) I (NA/COG) NP Fouladi 2015 
Sorafenib  20 10 (2 SD) II (NA/COG) NP Kim, 2015 
Dalotuzumab/Ridaforolimus 24 1 (none) I (EU/NA) FP Frappaz 2016 
Total 
 
2.571 
 
214 
(5 CR; 15 PR; 13 SD) 
 
 
 
 Abbreviations: COG, Children’s Oncology Group; CR, Complete response; FP, For-profit; EU, Europe; ITCC, Innovative 
Therapies for Children with Cancer; SD, Stable disease; PR, Partial response; NA, North America; NP, Non-profit; NR, 
Not reported; PC, Pediatric oncology therapeutic investigators experimental consortium; POG, Pediatric Oncology 
Group; WT, Wilms’ tumour 
 
1trials designed for Wilms tumour alone. 2it is not explicitly stated whether Wilms tumour stabilization was observed. 
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Table 3 Tumour response according to intervention with conventional chemotherapy or 
novel agents in patients with Wilms tumours  
Response 
Intervention 
Complete 
Response (%) 
Partial  
Response (%) 
Stable  
Disease (%) 
Progression 
(%) 
Novel agent 
monotherapy 
 (N = 99) 
 
0 (0%) 
 
1 (1%) 
 
7 (7%) 
 
91 (91%) 
Predominantly 
chemotherapy 
(N = 115) 
 
5 (4%) 
 
14 (12%) 
 
6 (5%) 
 
90 (78%) 
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Appendix B: Wilms’ tumours on biological/targeted treatment in phase I or II trials. 
Accumulated number of patients and the number of responders for each novel agent 
irrespective whether it has been used alone or in combination with other drugs. 
 
Type of biological treatment Number of trials 
(WT patients) 
Response 
Immunotherapy 
Viruses 
Adenovirus  
Seneca Valley virus  
Reovirus 
 
1 (1) 
1 (3)  
1 (3) 
1 PR 
2 SD 
Racotumomab (tumor antigen NGcGM3 active vaccine) 1 (1)  
Antibodies 
Bevacizumab (VEGF) 
Cetuximab (EGFR) 
Cixutumumab (IGF-1R) 
Dalotuzumab (IGF-1R) 
Lexatumumab (TRAIL-R2) 
 
4 (7) 
 1(1) 
3 (11) 
1 (1) 
1 (1) 
 
2 CR, 1 PR 
1 SD 
1 SD 
 
 
rTNFα 1 (19) 3 CR, 5 SD 
Interferon-α2A 1 (14)  
Thalidomide 
Lenalidomide 
1(3) 
2(5)  
Other targeted therapies 
Angiogenesis inhibitors 
Aflibercept (Ligand-binding) 
Cediranib (VEGFR) 
Pazopanib (VEGFR) 
Dasatinib (ABL) 
Sorafenib  (VEGFR) 
 
1(1) 
1(1) 
1 (1) 
1(1) 
4 (19) 
 
 
2 SD 
 
 
2 SD 
Mammalian target of rapamycin (mTOR) inhibitors 
Ridaforolimus  
Temsirolimus  
2 (2) 
2 (3)  
Histone deacetylase inhibitors 
Depsipeptide  
Valproic acid  
Vorinostat  
 
1 (2) 
1 (1) 
1 (1) 
 
Alisertib (aurora A kinase inhibitor)  1 (2)  
Bortezomib (proteasome inhibitor) 1 (1)  
Ispinesib (kinesin spindle protein inhibitor)  1 (2)  
Crizotinib (ALK/c-met inhibitor) 1 (1)  
Gefitinib (EGFR inhibitor) 1 (2) 2 SD 
MK2206b (protein kinase B (AKT), inhibitor) 1 (1)  
Flavopiridol (cyclindependent kinase inhibitor) 1 (1)  
Imetelstat (telomerase inhibitor) 1 (1)  
17-allylaminogeldanamycin (heat shock protein inhibitor) 1 (2)  
G3139 (inhibition of bcl-2 expression) 1 (5)  
Celecoxib (selective cyclooxygenase-2 (COX-2) inhibitor) 1 (3)  
Differentiating agents 
All-trans-retinoic acid (vitamin A analogue) 
Fenretinide (synthetic retinoid derivative) 
 
1 (14) 
1 (1) 
 
Abbreviations: ALK, anaplastic lymphoma kinase; CR, Complete response; EGFR, epidermal growth factor 
receptor; IGF-1R, insulin-like growth factor-1 receptor; SD, Stable disease; PR, Partial response; VEGF, vascular 
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endothelial growth facto; VEGFR, vascular endothelial growth factor receptor; WT, Wilms’ 
tumour. 
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Appendix C: Wilms’ tumours on conventional chemotherapy in a phase I or II trials. 
Accumulated number of patients and the number of responders for each chemotherapeutic 
irrespective whether it has been used alone or in combination with other drugs. 
 
Type of chemotherapy  Number of trials 
(WT patients) 
Response 
Alkylating agents  
Carboplatin 
Cisplatin  
Cyclophosphamide 
Ifosfamide 
Oxaliplatin 
Temozolomide 
 
1 (2) 
1 (2) 
5 (14) 
1 (1) 
5 (10) 
4 (8) 
 
1 SD 
 
 
 
 
2 CR, 1 PR 
Antimetabolites 
Gemcitabine 
Pemetrexed  
2 (6) 
1 (1) 
 
 
 
Anti-tumor antibiotics 
Doxorubicin 
Actinomycin D 
2 (6) 
1 (19) 
 
3 CR, 5 SD 
Topoisomerase inhibitors (I, II) 
Topotecan  
Irinotecan  
Etoposide 
Rebeccamycin analogue  
2 (27) 
10 (30) 
1 (4) 
1 (7) 
12 PR 
2 CR, 2 PR, 1 SD 
 
 
Mitotic inhibitors 
ABT-751 
Docetaxel  
Paclitaxel 
Ixabepilone 
Vincristine  
1 (2) 
1 (9) 
1 (1) 
2 (12) 
3 (8) 
 
 
 
1 SD 
2 CR, 1 PR 
Other 
Plitidepsin  
Trabectedin   
1 (4) 
1 (2)  
Abbreviations: CR, Complete response, SD, Stable disease; PR, Partial response; WT, Wilms’ tumour 
 
 
 
